한국어
미제공
과학 프로그램 2 일 차
English
한국어
미제공
Explore the Agenda
일정 확인하기
7:00 am Check-In & Morning Coffee
7:50 am Chair’s Opening Remarks
Combining Precision & Potency: Insights Into Dual Payload ADCs & Their Advantages in Overcoming Resistance
Mechanisms & Maximizing Tumor Cell Killing
8:00 am Exploring Next-Generation ADCs: Future Insight for Dual Payload ADCs
- Showcasing traditional cytotoxic ADC development and combination of IO drug, headlined by the approval and success of Padcev
- Exploring next-generation ADCs delivering an immune agonist payload and their expansion toward next-generation immunostimulatory dual payload ADC
- Discussing a strategy for a next-generation ADC, challenges and solutions
8:30 am Synaffix/Lonza End-to-End Offering to Best-in-Class Targeted-Therapies Based on GlycoConnect® & HydraSpace® Technologies
- Exploring how GlycoConnect® and HydraSpace® technologies enable ADCs with best-in-class therapeutic potential
- Sharing clinical development insights on the rapidly advancing pipeline of GlycoConnect® ADCs by partners
- Discussing technology expansion towards bispecific (bYlok®) and dual warhead ADCs with compelling in vivo data
- Presenting unprecedented mRNA exon skipping and dystrophin restoration in preclinical mouse model for Duchenne muscular dystrophy
9:00 am Reimagining ADC Design Through Enzymatic Conjugation: Enabling Site-Specific & Dual-Payload ADCs
- Analyze how GlycOBI® is a glycan site-specific conjugation platform enabling programmable DAR control, highlighting how precise glycan engineering supports homogeneous ADCs and tunable drug loading
- Assess how linker design and DAR tuning are key determinants of ADC stability and pharmacokinetics, with mechanistic insights into how linker architecture and DAR optimization jointly influence circulation stability and exposure
- Outline dual-payload ADC design principles, including the impact of distinct conjugation sites and payload release efficiencies, and a case study illustrating the rational design of a bispecific dual-payload ADC to overcome resistance mechanisms
9:30 am Harnessing ADC Design Strategies for Next-Generation AOCs
- Expanding architecture of linker payload and conjugation modality for AOCs
- Solving the challenges of next-generation conjugates using Thiobridge® technology
- Supporting characterization and manufacture of bioconjugates through Abzena’s integrated offering
10:00 am Refreshment Break
10:30 am Networking
This is your opportunity to have face-to-face conversations with fellow attendees of the World Targeted Therapeutics Summit South Korea by Hanson Wade. Progress your ADC candidates forward and make connections with global pharma and biotech working on ADCs, targeted protein degradation, induced proximity, bispecifics, and T-Cell engagers, as well as global service providers, in a mix of pre-organized and random networking.
Discovery Track
Optimizing ADC Design Through Linker Engineering & Target Selection to Boost ADC Safety & Broaden the Therapeutic Scope
11:30 am Self-Immolative Phosphoramidates to Expand The Payload Scope in Antibody-Drug Conjugates by Delivery of Hydroxy-Containing Drugs
Vice President, Chemistry & Early Discovery, Tubulis
- Explore how payloads of current marketed ADC are limited to three Modes of Action (MoAs): DNA binders, Tubulin- and TOP-I-Inhibitors
- Present novel linker technologies for stable conjugation and traceless release of hydroxy-containing drugs to expand the payload space in ADCs
- Discuss how resulting ADCs are homogenous at high DAR, have excellent linker stability, and exhibit unprecedented in vivo PK and efficacy
12:00 pm Examining Photomedicine ADCs: Spatial & Temporal Photo-Activation
Professor & Faculty Fellow, Northeastern University
- Overview the advantages of photomedicine
- Explore photo-cleavable linkers for spatial andtemporal activation
- Discuss the related topic on photodynamic therapy (PDT), i.e., photosensitizer-antibody conjugate (PAC)
12:30 pm Discovery & Preclinical Characterization of PBX-004, Potential Best-In-Class ITGB6 Targeting ADC
Founder & Chief Executive Officer, Pinot Bio
- Introducing design of PBX-004, potential best-in-class ADC targeting ITGB6
- Highlighting efficacy and safety data of PBX-004 obtained in preclinical development
- Leveraging proprietary Top1i payload, PBX-7016 to achieve good efficacy/safety balance of ADC
Preclinical Track
CMC Track
1:00 pm Lunch
Combining Precision & Potency: Insights Into Dual Payload ADCs & Their Advantages in Overcoming Resistance
Mechanisms & Maximizing Tumor Cell Killing
2:00 pm Panel Discussion: Understanding Large Pharma’s Thought-Process on Establishing Partnerships With Innovative Biotech to Inform Your Development Strategy
- Understanding the pharma priorities when it comes to licensing and partnerships
- Discussing strategies for collaborating that align with scientific and business opportunities
- Identifying the best path for collaborations to ensure successful alliances
3:00 pm Refreshment Break
Harnessing Novel Targets, Innovative Payloads & Conjugation Platforms to Effectively Treat Harder to Treat Cancers & Progress ADCs to the Front Line of Cancer Treatment
3:30 pm Analyzing Phase I Results of DLL3-Targeted ADC Zocilurtatug Pelitecan in Patients With Small Cell Lung Cancer to Understand the Potential of Next-Generation ADCs in Treating Hard to Treat Cancers
- Demonstrating clinical activity and safety profile of Zocilurtatug Pelitecan
- Discussing the impact this success has on furthering next-generation ADC development
- Identifying the next steps for downstream development
4:00 pm Exploring the Success of Dxd ADC Platform in Optimizing Clinical Efficacy Through Plasma-Stable Linker-Payload Technology & Optimized DAR
- Analyzing the design innovations of the DXd ADC platform, specifically the plasma-stable linker-payload to understand its role in enhancing tumor selectivity
- Discussing translational and clinical outcomes of this platform in achieving efficacy in multiple tumor types
- Demonstrating bystander antitumor effect and its enhanced ability in tumor killing
4:30 pm Novel Multi-Payload ADCs Assembled in One Step From Native Antibodies Show High Efficacy & Tolerability In Vivo
- Presentation of AraLinQTM: the Araris conjugation technology enabling the synthesis of multi-payload ADCs in one step
- Addressing the limitations of current mono-payload ADCs by combining payloads with distinct modes of action
- Sharing examples of dual- and triple-payload ADCs prepared using the Araris technology demonstrating high efficacy and tolerability in vivo